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This study examines the distinct gene expression profile of peripheral blood mononuclear
cells from patients with chronic hepatitis C infection and mixed cryoglobulinemic (MC) vas-
culitis. Our DNA microarray analysis indicates that hepatitis C virus (HCV)-associated MC
vasculitis is characterized by compromised neutrophil function, impaired chemotaxis, and
increased interferon-stimulated gene (ISG) expression, contributing to overall MC patho-
genesis and end-organ damage. Increased ISG expression is suggestive of an enhanced
endogenous interferon gene signature. PBMC depletion assays demonstrate that this
increased expression is likely due to an activation of monocytes and not a direct result
of B cell expansion. Notably, this monocyte activation of ISG expression in HCV-associated
MC vasculitis suggests a poor predictor status of interferon-based treatment. Further analy-
sis of PBMC gene expression profiles before and after in vivo B cell depletion therapy is
critical to completely understanding the mechanisms of MC vasculitis pathogenesis.
Keywords: hepatitis C, mixed cryoglobulinemia, vasculitis, interferon-stimulated genes
INTRODUCTION
Chronic hepatitis C (CHC) infection affects 180 million people
worldwide (1). Hepatitis C virus (HCV) is a single-stranded RNA
virus that preferentially infects hepatocytes of the liver (2). CHC
can lead to progressive liver fibrosis, cirrhosis, hepatocellular car-
cinoma, and death (3). CHC has also been associated with several
extrahepatic manifestations, among which include mixed cryo-
globulinemic (MC) vasculitis, lymphoproliferative disorders, and
insulin resistance (4, 5). Of these, Type II MC vasculitis is the most
common and directly attributed to CHC (6), with CHC identified
in more than 80% of patients with persistent MC vasculitis (7, 8).
Hepatitis C virus-associated MC vasculitis is characterized by
an expansion of monoclonal B cells probably triggered by HCV
antigens (6, 9). These clonal B cells produce IgM with rheuma-
toid factor activity, which can lead to the formation and depo-
sition of immune complexes and eventual small vessel vasculitis
(6, 9). The end result is tissue and organ damage, particularly
of the kidneys and skin, the common clinical manifestations
being membranoproliferative glomerulonephritis and cutaneous
vasculitis (4, 10).
Recent studies have demonstrated that patients diagnosed with
MC vasculitis can be effectively treated with B cell depletion
therapy (11–13). However, the role of B cells in a variety of
immunological abnormalities associated with MC and the exact
nature of how CHC infection affects the pathogenesis of MC
vasculitis are not completely understood. In particular, whether
monoclonal B cell expansion can lead to activation of other
immune cells to further contribute to the pathogenesis is not
clear. In this study, we performed gene expression profile analysis
of PBMCs from four different patient cohorts to determine the
change in gene expression among HCV-associated MC vasculitis
patients compared to other subjects with and without HCV and
vasculitis.
MATERIALS AND METHODS
STUDY DESIGN AND PATIENT POPULATION
PBMCs were isolated by venipuncture from normal volunteers
(N = 12), HCV monoinfected subjects (N = 7), human immun-
odeficiency virus (HIV) and HCV coinfected subjects on antiretro-
viral therapy (N = 5), and HCV MC vasculitis subjects (N = 7)
(Table 1). HIV was diagnosed by ELISA and Western blot using the
Cambridge Biotech HIV-1 Serum Western Blot Kit (Maxim Bio-
medical, Rockville, MD, USA). HIV RNA was quantified byVersant
HIV RNA 3.0 Assay (Bayer Diagnostics, Puteaux Cedex, France).
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Table 1 | Demographics and clinical characteristics of study participants.
Group Age Gender Race Risk HCV GT HCVVL HIVAb HIVVL TCD4 CD4% Systemic
corticosteroids
Clinical manifestations of MC
vasculitis
Normal volunteer 1 41 F White N/A N/A N/A Negative N/A
Normal volunteer 2 34 M White N/A N/A N/A Negative N/A
Normal volunteer 3 56 F White N/A N/A N/A Negative N/A
Normal volunteer 4 37 F Black N/A N/A N/A Negative N/A
Normal volunteer 5 42 M White N/A N/A N/A Negative N/A
Normal volunteer 6 46 F White N/A N/A N/A Negative N/A
Normal volunteer 7 39 M Hispanic N/A N/A N/A Negative N/A
Normal volunteer 8 45 M White N/A N/A N/A Negative N/A
Normal volunteer 9 38 F White N/A N/A N/A Negative N/A
Normal volunteer 10 46 M White N/A N/A N/A Negative N/A
Normal volunteer 11 41 F Black N/A N/A N/A Negative N/A
Normal volunteer 12 27 W Male N/A N/A N/A Negative N/A
HIV/HCV 1 49 M Black IVDU 1a 7,692,310 Positive 121 1,233 45
HIV/HCV 2 40 M Black MSM 1a 4,976,400 Positive <50 1,460 44
HIV/HCV 3 51 M Black IVDU 1b 3,945,420 Positive <50 727 30
HIV/HCV 4 49 F Black IVDU 1a 1,054,510 Positive <50 794 25
HIV/HCV 5 55 M Black MSM 1b 9,504,730 Positive <50 1,008 43
HCV 1 51 M White IVDU 1b 2,500,000 Negative N/A
HCV 2 53 F White IVDU 1a 473,000 Negative N/A
HCV 3 51 M Black IVDU 1 441,000 Negative N/A
HCV 4 45 M White IVDU 1a 3,820,000 Negative N/A
HCV 5 42 M White IVDU 2 10,900,000 Negative N/A
HCV 6 59 F Black IVDU 2b 7,810,000 Negative N/A
HCV 7 70 M White IVDU 1b 3,830,000 Negative N/A
HCV MC Vasc 1 56 M White Needlestick 1a 3,419,770 Negative N/A Arthralgia, purpura, peripheral
neuropathy
HCV MC Vasc 2 52 M White Transfusion
acquired
1a, 1b 1,864,910 Negative N/A Prednisone 10 mg daily Arthritis, purpura, peripheral
neuropathy
HCV MC Vasc 3 47 F White IVDU 2b 2,296,250 Negative N/A Peripheral neuropathy, hematuria
HCV MC Vasc 4 56 M White Intranasal cocaine 1a 50,816 Negative N/A Purpura, glomerulonephritis
HCV MC Vasc 5 47 M White Intranasal cocaine 1a 932,880 Negative N/A Prednisone 50 mg daily Purpura, ulcers, mononeuritis
HCV MC Vasc 6 56 M White IVDU 1a 100,907 Negative N/A Arthralgia, purpura, peripheral
neuropathy
HCV MC Vasc 7 58 F White IVDU 1 <615 Negative N/A Prednisone 30 mg daily Purpura, ulcers, hematuria
HIV and HCV viral loads were measured by the Versant RNA 3.0 Assay with a lower limit of detection of 50 copies/ml and 615 IU/ml, respectively. qRT-PCR results are shown only for 5 of the 12 healthy volunteers
and 6 of the 7 HCV monoinfected subjects due to availability of samples. Samples for the other seven normal volunteer patients were used to validate microarray analysis in Kottilil et al. (14). Additionally, B cell
depletion experiments were only done on subsets of individuals as determined by sample availability.
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HCV genotype was determined by the INNO-LiPA HCV II (Inno-
genetics) assay and HCV RNA was quantified by the Versant HCV
RNA 3.0 Assay (Bayer Diagnostics, Tarrytown, NY, USA).
Normal volunteers were selected through the blood bank and
were HIV and HCV negative. HIV/HCV coinfected patients and
the HCV monoinfected patients were selected from an ongoing
longitudinal study at the National Institutes of Health (NIH). The
HCV MC vasculitis subjects were selected from an ongoing open-
label, randomized controlled trial conducted at the NIH (13).
Inclusion in this trail required the presence of active manifestations
of MC vasculitis as described in Sneller et al. (13). Only patients
who did not respond to or tolerate interferon-alpha and ribavirin
over a year before start of this study were enrolled. Patients were
allowed to continue taking corticosteroids, but samples were col-
lected before the day’s dose, at steroid trough level, to minimize
the immunomodulatory effects of these drugs. All donors signed
informed consents approved by the National Institute of Allergy
and Infectious Diseases Institutional Review Board. Clinical proto-
cols NCT00029107, NCT00001281, and NCT00076427 were used
to enroll study subjects.
ISOLATION OF PBMCs AND RNA
PBMCs were isolated from white blood cells by the standard Ficoll-
Hypaque Plus (Amersham Biosciences, Uppsala, Sweden) density
gradient separation technique and then frozen for storage. RNA
was isolated using the Qiagen mRNA isolation kit (Qiagen, Ger-
mantown, MD, USA) following the manufacturer’s protocol and to
be used for DNA microarray and quantitative reverse transcription
polymerase chain reaction (qRT-PCR) analysis.
DNA MICROARRAY ANALYSIS
Complementary RNA was prepared from total RNA and
hybridized to Affymetrix U133A 2.0 oligonucleotide arrays accord-
ing to the manufacturer’s protocols (Affymetrix, Santa Clara,
CA, USA) as previously described (14). A significant analysis of
microarray (SAM) algorithm was used to determine the genes that
were differentially expressed after an extensive filtering process.
Genes with low variability or undetectable expression levels (for
the majority of samples) were eliminated from analysis if the
Guanosine–Cytosine Robust Multi Array values for these genes
were within the interquartile range of <0.263 or a 75th percentile
of <5. The corresponding genes and samples from the individuals
were then subjected to hierarchical clustering.
REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE
CHAIN REACTION
Total RNA isolated from PBMCs was reverse-transcribed using
random primers with the High Capacity cDNA Reverse Transcrip-
tase Kit (Life Technologies). Between 1 and 25 ng of RNA was used
for each quantitative qRT-PCR reaction. Taqman expression assays
were run with technical duplicates except where indicated (Life
Technologies). Primer/probe sets were pre-designed for respective
genes and purchased from Life Technologies. Gene expression was
determined as a cycle at threshold (Ct) based on 40 PCR cycles. For
statistical analysis, undetectable expression was assigned a mini-
mal detectable level with a Ct value of 40. Expression of GAPDH
was used as an endogenous control, with GAPDH Ct values for all
samples being distributed between 20 and 25. Relative expression
of targets was calculated as dCt values (normalized by GAPDH
Ct values) or ddCt values (to calculate fold change compared to
other samples). Expression reactions were run in 96-well plates on
a 7500 Real-Time PCR System (Applied Biosystems).
STATISTICAL ANALYSIS
ANOVA with Tukey’s multiple comparison test was used to com-
pare means of the relative gene expression in independent groups.
The paired T -test with the Bonferroni adjustment for multiple
testing was used to compare paired responses.
PBMC DEPLETION AND ENRICHMENT ASSAY
Total PBMCs were isolated using Ficoll-Hypaque density gradi-
ent centrifugation. B cells (CD19 pan B dynabeads) and mono-
cytes (CD14 dynabeads) were either depleted or enriched using
an antibody-coated magnetic bead column separation technique
(Life Technologies, Grand Island, NY, USA). Dynabeads CD19 pan
B and CD14 are both uniform (4.5µm diameter) superparamag-
netic beads coated with a primary monoclonal antibody specific
for the CD19 or CD14 membrane antigen mainly expressed on
human B cells and monocytes, respectively. Cell purity for B cells
was performed as follows using flow cytometry and was deter-
mined to be >90%. Cells were stained for CD3 APC (Clone
UCHT1) and CD20 FITC (Clone: L27) (source for both antibod-
ies: BD Biosciences, San Jose, CA, USA) and analyzed using a FAC-
SCanto Cell Analyzer (BD Biosciences, San Jose, CA, USA). Cells
were analyzed using a lymphocyte gate and purity was assessed
as CD3−CD20+ lymphocytes. For monocytes, purity was assessed
by staining cells for CD3 APC (Clone UCHT1) and intracellular
CD68 FITC (Clone Y1/82A) (source: BD Biosciences, San Jose,
CA, USA) after permeabilization and fixing. The cells were ana-
lyzed using a monocyte gate and purity assessed as CD3−CD68+
cells.
RESULTS
STUDY SUBJECTS
Five patient cohorts were analyzed: normal volunteers, HCV
monoinfected subjects, HIV/HCV coinfected subjects, and HCV
MC vasculitis subjects (Table 1).
Human immunodeficiency virus/hepatitis C virus coinfected
patients were of interest to us because coinfection with HCV is
present in one-third of all HIV-infected individuals and the gene
expression profiles of coinfected patients has already been charac-
terized (14). Additionally, HIV infection drives T cell activation
and MC vasculitis drives B cell activation. This patient group
thus serves as an additional comparison to better understand how
the pathogenesis of HCV-associated MC vasculitis pathogenesis
induces a gene expression profile distinct from the other common
HCV-infected patient cohorts.
Hepatitis C virus MC vasculitis subjects were selected based
on the presence of active manifestations of CHC-associated MC
vasculitis and required the presence of peripheral neuropathy,
cutaneous vasculitis, and/or glomerulonephritis. Common clin-
ical manifestations included purpura, arthralgia, hematuria, and
ulcers. Patients with the presence of potentially life-threatening
vasculitis involving the heart, central nervous system, or gastroin-
testinal tract were excluded. It should also be noted that three
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out of the seven HCV MC vasculitis patients were on prednisone
and did not have a change in immunosuppressive therapy within
4 weeks of study entry. For these study subjects, samples were
drawn as trough (23 h post morning dose of prednisone) to min-
imize the effect of corticosteroids on the immune system. Addi-
tionally, HCV MC vasculitis patients with prior use of rituximab,
severe renal insufficiency, severe hepatic insufficiency, lymphoma,
coinfection with HIV or hepatitis B virus, liver transplantation, or
active systemic infections were excluded (13).
DIFFERENTIAL GENE EXPRESSION PROFILES IN PBMCs OF HCV MC
VASCULITIS SUBJECTS
To compare the host gene expression profile induced by HCV
infection with MC vasculitis to that induced by HCV monoinfec-
tion and HCV/HIV coinfection without MC, we performed DNA
microarray analysis using RNA isolated from PBMCs from the
aforementioned patient groups (Table 1).
Using Affymetrix human genome U133A oligonucleotide
arrays and a SAM algorithm, we identified a total of 529 differen-
tially expressed genes between the four groups (Figure 1). The cor-
responding genes and samples from the individuals were subjected
to hierarchical clustering, which revealed four distinct clusters of
differential gene expression (Figure 1). Cluster 1 consists of 192
genes that are down-regulated in both HCV monoinfected patients
and HCV MC vasculitis patients. Functional annotation analysis
revealed that these genes share roles in cellular defense. Cluster
2 includes 41 genes that are up-regulated in HCV monoinfected
patients when compared to HCV MC vasculitis subjects and are
mostly genes implicated in chemotaxis and response to exter-
nal stimulus. Cluster 3 consists of 284 genes including several
interferon-stimulated genes (ISGs) that are up-regulated only in
HCV MC vasculitis patients. Cluster 4 includes 12 heat shock
proteins that are down-regulated in HCV MC vasculitis patients.
Representative genes that belong to each cluster were identified
by rigorous literature-mining algorithms, significance of microar-
ray analysis, and biology of the disease processes of both HCV
viremia and MC vasculitis (Tables A1–A3 in Appendix) and val-
idated by qRT-PCR. This process of gene selection is consistent
with our previous studies (14).
DOWN-REGULATION OF CELLULAR DEFENSE GENES IN HCV
MONOINFECTED PATIENTS WITH OR WITHOUT MC VASCULITIS
To validate our DNA microarray analysis, we performed qRT-PCR
analysis on the most biologically relevant genes from each cluster
selected as described above. Total RNA was extracted from the
PBMCs and subjected to qRT-PCR using primers specific for the
validated genes.
Cluster 1 was comprised of genes involved in cellular defense,
which were down-regulated in patients monoinfected with HCV,
with or without vasculitis. We chose to measure transcript levels of
defensin alpha-1 and defensin alpha-4 (Figure 2). The mean gene
expression of defensin alpha-1 was significantly lower in HCV
monoinfected and HCV MC vasculitis patients compared to the
other two groups [3.80± 0.80 (NV), 1.20± 0.40 (HCV MC-Vasc),
FIGURE 1 | Clustering of differentially expression genes in PBMCs from
four patient cohorts. Levels of gene expression were assayed using
Affymetrix Human Genome U133A chips as described in the methods
section. A total of 529 differentially expressed genes were identified. Genes
were grouped using K -means clustering, and samples were grouped by
hierarchical clustering. Differences in relative levels of gene expression
(Z -score) are represented by color, where red indicates up-regulation and
green indicates down-regulation relative to that of corresponding gene
expression in controls. The numbers in parentheses specify the number of
genes in each cluster. Cluster 1 consists of genes down-regulated in HCV
monoinfected patients and HCV MC vasculitis patients. Cluster 2 consists of
genes up-regulated in HCV monoinfected patients without vasculitis. Cluster
3 consists of genes up-regulated in HCV MC vasculitis patients and Cluster 4
consists of genes down-regulated in HCV MC vasculitis patients.
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FIGURE 2 |Validation of Cluster 1 microarray data by qPCR analysis.
DNA microarray expression of biologically relevant genes selected from
Cluster 1 was validated using qRT-PCR as described in the Section
“Materials and Methods.” Levels of mean gene expression were calculated
in comparison to the expression of GAPDH. The expression of defensin
alpha-1 (A) and defensin alpha-4 (B) were lower in the HCV monoinfected
(p=0.03 and 0.04 with normal, respectively) and HCV MC vasculitis
cohorts (p=0.01 and 0.03 with normal, respectively).
2.10± 0.60 (HCV), 3.7± 0.70 (HIV/HCV); p= 0.01 between
HCV MC-Vasc and normal and p= 0.03 between HCV viremic
and normal], thereby confirming the DNA microarray analysis.
This was similarly true for defensin alpha-4 [4.30± 0.40 (NV),
2.00± 0.90 (HCV MC-Vasc), 2.50± 0.60 (HCV), 3.90± 0.80
(HIV/HCV); p= 0.03 between HCV MC-Vasc and normal and
p= 0.04 between HCV viremic and normal]. Defensins are pro-
teins expressed in neutrophils that have broad anti-microbial
properties (15). Our results suggest a selective depletion of
the inflammatory capacity of neutrophils seen in patients with
HCV infection. Although this down-regulation of alpha-defensin
expression levels are not seen in the HIV/HCV coinfected cohort,
alpha-defensins have been shown to be elevated in HIV-infected
patients (16).
HCV MONOINFECTION UP-REGULATES EXPRESSION OF GENES
INVOLVED IN CHEMOTAXIS AND RESPONSE TO EXTERNAL STIMULI
Cluster 2 is comprised of genes that are up-regulated in HCV
monoinfected patients without vasculitis and play a role in chemo-
taxis and response to external stimuli. We validated the microarray
analysis by comparing the expression levels of four genes in this
cluster, chemokine (C-C motif) ligand 4 (CCL4), chemokine (C-
X-C motif) ligand 1 (CXCL1), cluster of differentiation 69 (CD69),
and chemokine (C-C motif) ligand 20 (CCL20) by qRT-PCR
(Figure 3).
Chemokines are a family of cytokines responsible for medi-
ating leukocyte chemotaxis (17). Transcript levels of CCL4, a
lymphocyte attractant (18), were significantly higher in HCV
viremic patients when compared to the three other subject cohorts
[3.20± 0.80 (NV), 1.90± 0.70 (HCV MC-Vasc), 5.40± 0.90
(HCV), 2.80± 1.00 (HIV/HCV); p= 0.02 between HCV viremic
and HCV MC-Vasc]. Similarly, CXCL1, a chemokine with neu-
trophil chemotactic activity (19), was up-regulated in HCV
monoinfected patients [2.80± 0.90 (NV), 3.20± 0.60 (HCV
MC-Vasc), 5.70± 0.50 (HCV), 4.10± 0.70 (HIV/HCV); p= 0.04
between HCV viremic and HCV MC-Vasc]. CD69 is a receptor that
is induced upon antigen-associated activation of T cells and trans-
mits signals to other lymphocytes (20). PBMC expression of CD69
was greater in the HCV monoinfected cohort [3.90± 0.80 (NV),
3.40± 0.90 (HCV MC-Vasc), 5.80± 0.80 (HCV), 4.80± 0.70
(HIV/HCV); p= 0.04 between HCV viremic and HCVMC-Vasc].
Finally, CCL20 showed similar gene expression patterns among the
patient cohorts [4.90± 0.80 (NV), 3.80± 0.70 (HCV MC-Vasc),
6.50± 0.70 (HCV), 5.40± 0.80 (HIV/HCV); p= 0.03 between
HCV viremic and HCV MC-Vasc]. These data further validate
the microarray analysis and demonstrate that genes involved in
chemotaxis and response to external stimuli are up-regulated in
HCV monoinfected individuals relative to HCV MC vasculitis
patients. In extension, these data suggest that the HCV MC vas-
culitis patient cohort has an impaired chemotactic response to
stimuli.
PBMCs OF HCV-ASSOCIATED MC VASCULITIS PATIENTS SHOW
INCREASED EXPRESSION OF ISGs
Our analysis of Cluster 3 demonstrates an enrichment of ISGs
in the HCV MC vasculitis cohort. We chose to validate the
gene expression of 2′-5′-oligoadenylate synthetase-like protein
(OASL), TIMP metallopeptidase inhibitor 1 (TIMP1), interferon
regulatory factor 2 binding protein 2 (IRF2B2), and chemokine
(C-X-C motif) ligand 16 (CXCL16) (Figure 4). OASL is an IFN-
induced cellular protein that inhibits viral replication of HCV
(21). Gene expression of OASL was higher in HCV MC vasculitis
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FIGURE 3 |Validation of Cluster 2 microarray data by qPCR analysis.
DNA microarray expression of biologically relevant genes selected from
Cluster 2 was validated using qRT-PCR as described in the Section
“Materials and Methods.” Levels of mean gene expression were
calculated in comparison to that of GAPDH. The expression of CCL4 (A),
CXCL1 (B), CD69 (C), and CCL20 (D) were higher in the HCV
monoinfected cohort compared to the other groups (p=0.02, 0.04, 0.04,
and 0.03, respectively compared to HCV MC-Vasc).
patients compared to the other subject cohorts [2.20± 0.50 (NV),
4.30± 0.90 (HCV MC-Vasc), 2.20± 0.80 (HCV), 2.70± 0.40
(HIV/HCV); p= 0.02 between HCV MC-Vasc and HCV viremic].
TIMP1 regulates extracellular matrix (ECM) turnover and remod-
eling by inhibiting the degradation of ECM (22). Transcript levels
of TIMP1 were significantly higher in the HCV MC vasculitis
cohort [1.80± 0.70 (NV), 4.8± 1.10 (HCV MC-Vasc), 2.80± 0.70
(HCV), 2.90± 1.00 (HIV/HCV); p= 0.03 between HCV MC-
Vasc and HCV viremic]. Interferon regulatory factor 2 binding
protein (IRF2BP2) is a co-repressor of type I IFN genes and
many ISGs (23). The HCV MC vasculitis cohort had greater gene
expression of IRF2BP2 when compared to the other study groups
[2.10± 0.90 (NV), 5.10± 0.80 (HCV MC-Vasc), 3.10± 0.90
(HCV), 3.40± 0.80 (HIV/HCV); p= 0.03 between HCV MC-Vasc
and HCV viremic]. Finally, CXCL16 is an interferon-gamma-
regulated cytokine that promotes cell growth and migration and is
also involved in lymphocyte chemotaxis (24). qRT-PCR validated
the microarray analysis indicating that CXCL16 gene expression is
up-regulated in HCV MC vasculitis patients [1.90± 0.60 (NV),
4.60± 0.80 (HCV MC-Vasc), 2.50± 0.60 (HCV), 3.10± 0.50
(HIV/HCV); p= 0.02 between HCV MC-Vasc and HCV viremic].
Thus, our data suggest that the MC vasculitis patient cohort
express higher levels of ISGs at the transcript level than the other
groups with or without HCV infection.
EVIDENCE FOR ACTIVATION OF MONOCYTES IN HCV-ASSOCIATED MC
VASCULITIS
In order to determine which cells contribute to this increased
ISG expression observed in the MC vasculitis patients, we per-
formed enrichment and depletion studies in PBMCs for B cells
and monocytes. The expression of ISGs in each cell subset was
then quantified.
Our data indicate that B cell enrichment and depletion of
PBMCs have no effect on ISG expression levels (Figure 5). As
shown in Figure 5, the mean gene expression of ISGs MAX interac-
tor 1 (MX1), 2′-5′-oligoadenylate synthetase (OAS1), interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1), and
interferon-induced protein 44 (IFI44) was not statistically signifi-
cant between PBMCs, B cell enriched PBMCs, and B cell depleted
PBMCs. These results suggest a novel observation that the increase
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FIGURE 4 |Validation of Cluster 3 microarray data by qPCR analysis. DNA
microarray expression of four relevant ISGs selected from Cluster 3 was
validated by qRT-PCR as described in the Section “Materials and Methods.”
Levels of mean gene expression were calculated in comparison to that of
GAPDH.The expression of OASL (A), TIMP1 (B), IRF2BP2 (C), and
CXCL16 (D) was up-regulated in the HCV MC vasculitis cohort compared to
the other groups (p= 0.02, 0.03, 0.03, and 0.02, respectively between HCV
MC-Vasc and HCV viremic).
in ISG expression seen among the HCV MC vasculitis patient
cohort is not directly due to the monoclonal expansion of B cells
in MC vasculitis pathogenesis.
However, levels of MX1 expression were significantly higher
in monocyte enriched PBMCs compared to the other cell subsets
[4.30± 0.80 (PBMC), 3.80± 0.70 (B cells), 4.20± 1.00 (B cells
depleted), 5.60± 0.80 (monocytes), and 3.67± 0.70 (monocytes
depleted); p= 0.02 between monocyte enriched and depleted].
This was also true of OAS1 [5.00± 0.90 (PBMC), 4.30± 0.80 (B
cells), 5.40± 0.90 (B cells depleted), 6.80± 0.60 (monocytes), and
4.20± 0.70 (monocytes depleted); p= 0.03 between monocyte
enriched and depleted], IFIT1 [4.80± 0.60 (PBMC), 4.10± 0.60
(B cells), 4.30± 0.60 (B cells depleted), 6.10± 0.80 (monocytes),
and 3.30± 0.60 (monocytes depleted); p= 0.01 between mono-
cyte enriched and depleted], and IFI44 [3.90± 0.60 (PBMC),
3.60± 0.70 (B cells), 3.70± 0.50 (B cells depleted), 5.50± 0.40
(monocytes), and 3.30± 0.50 (monocytes depleted); p= 0.03
between monocyte enriched and depleted].
The higher expression levels of ISGs in monocyte enriched
PBMCs compared to that seen in total PBMCs suggest that
monocytes are likely responsible for the increased ISG expression
among the HCV MC vasculitis cohort. Therefore, the probable
mechanism underlying increased ISG expression is the indirect
activation of monocytes by the monoclonal expansion of B cells
in MC vasculitis.
DISCUSSION
Mixed cryoglobulinemic vasculitis is a common extrahepatic man-
ifestation of CHC and can cause fulminant complications such as
glomerulonephritis. CHC-associated MC vasculitis is character-
ized by HCV-driven monoclonal expansion of B cells producing
IgM with rheumatoid factor activity (6, 9). These autoantibodies
form complexes with circulating IgG and HCV particles, which are
deposited in blood vessel and glomerular capillaries. The deposited
cryoglobulins can stimulate the complement system and activate
tissue damage and eventual end-organ damage, particularly of skin
and kidneys (6, 9). However, not much is known about the mech-
anisms that trigger HCV induction of MC in some patients with
CHC. Investigating the gene expression profile of HCV MC vas-
culitis patients is necessary to better elucidate the pathophysiology
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FIGURE 5 | Monocyte enrichment of PBMCs leads to increased ISG
expression. Expression of ISGs was quantified in total PBMCs, B cell
enriched PBMCs, B cell depleted PBMCs, monocyte enriched PBMCs, and
monocyte depleted PBMCs. Levels of mean gene expression of four selected
ISGs, MX1 (A), OAS1 (B), IFIT1 (C), and IFI44 (D), were calculated in
comparison to that of GAPDH. The expression of all four ISGs, MX1 (p= 0.02
between monocyte depleted and enriched), OAS1 (p=0.03 between
monocyte depleted and enriched), IFIT1 (p=0.01 between monocyte
depleted and enriched), and IFI44 (p= 0.03 between monocyte depleted and
enriched), was significantly higher in monocyte enriched PBMCs compared to
total PBMCs and monocyte depleted PBMCs, while no such differences were
observed when B cells were depleted.
of CHC-induced MC vasculitis. In this study, we demonstrate that
PBMCs from patients with HCV-associated MC vasculitis have a
distinct gene expression profile when compared to PBMCs from
patients with HCV and no vasculitis.
Overall, the gene expression profile of HCV-associated MC
vasculitis reflects compromised neutrophil function, impaired
chemotaxis, and an enhanced endogenous interferon gene signa-
ture. Notably, the peripheral ISG signature appears to be predomi-
nantly a result of the activation of monocytes, a novel observation
that helps to elucidate the pathogenesis in HCV MC vasculitis
patients. HCV MC vasculitis is thought to be primarily mediated
by monoclonal expansion of B cells. In this study, we were able to
demonstrate that other immune cells are also affected and con-
tribute significantly to the disease pathogenesis. We have shown
that elevated ISG expression, considered to be a bad prognostic
factor for clearing HCV, is mediated by monocytes in HCV MC
patients.
First, our microarray analysis suggests decreased cellular
defense gene expression in HCV monoinfected subjects, with
or without MC vasculitis. HCV has been shown to evade
host immune mechanisms (25, 26), consistent with the down-
regulation of defensins in the two HCV monoinfected patient
groups. The enhanced antibody-dependent cell cytotoxicity asso-
ciated with HCV MC vasculitis and leading to end-organ damage
is mediated in part by neutrophils (27). These results suggest a
depletion of alpha-defensin production in neutrophils either as a
result of exhaustion or due to the influence of systemic corticos-
teroid administration, which some subjects were receiving at the
time of the study. Due to the rare occurrence of HCV MC vas-
culitis and the lack of access to these patients, it was difficult to
find a subject cohort who was not taking systemic corticosteroids,
a limitation of our study. However, to ensure that the effects of
systemic corticosteroids were minimal, we drew trough research
samples 1 h before the daily dose of prednisone. Additionally, the
clinical manifestations of HCV MC vasculitis were similar among
all the patients whether or not they were taking corticosteroids.
Second, the presence of MC vasculitis appears to impair chemo-
taxis and response to external stimuli. The expression of several
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chemokines was down-regulated in HCV MC vasculitis patients
when compared to HCV monoinfected patients. In particular,
CCL20, involved in migration of lymphocytes to the liver (28),
had a greater than twofold down-regulation at the transcript level
in HCV MC vasculitis patients. These results suggest the presence
of aberrant chemotactic pathways that exist in HCV-associated
MC vasculitis as a result of an ongoing extrahepatic inflammatory
response. In HCV-infected subjects, the liver is the primary organ
of inflammatory response and the site of migration for immune
cells. However, in patients with MC vasculitis and HCV infection,
immune cells may in fact migrate to peripheral extrahepatic sites
such as the kidneys and/or skin. Markers such as CD69 that rep-
resent early activation of lymphocytes are not up-regulated in the
HCV MC vasculitis group, suggesting a distinct pattern of immune
activation in HCV MC patients than that observed with HIV/HCV
coinfected subjects.
Third, HCV MC vasculitis subjects also had increased expres-
sion of ISGs, an indicator of poor response to interferon-alpha-
based therapy. B cell enrichment had no effect on ISG expression
while monocyte enrichment of PBMCs led to significantly higher
levels of ISG expression. This is a novel observation demonstrat-
ing that activation of monocytes may contribute to the pathogenic
mechanisms in HCV MC vasculitis. Since most HCV MC vas-
culitis patients have undergone HCV treatment with interferon
and ribavirin, it is probable that the enhanced ISG induction is an
indicator of non-response and not specific to underlying vasculitis
(29, 30). Hence, further analysis of PBMC gene expression profiles
before and after in vivo B cell depletion is necessary to completely
elucidate this pathway of monocyte activation and the role played
by monoclonal B cells.
In summary, our study offers a preliminary analysis of the
differential regulation of host gene expression in subjects with
HCV-related MC vasculitis. Future studies will be focused on iden-
tifying the specific mechanisms behind the viral induction of B cell
proliferation and the role of B cells in increased ISG expression in
the context of B cell depletion therapy.
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APPENDIX
Table A1 | Genes down regulated in all HCV subjects compared to normal.
Gene ID Name Short name Function
1554479_a_at Caspase recruitment domain family,
member 8
CARD8 Inhibits NF-kappa B activation. Suppression of apoptotic
processes and inflammatory signaling pathways
203373_at Suppressor of cytokine signaling 2 SOCS2 Negative regulator of apoptotic processes and cytokine
signal transduction pathway
205798_at Interleukin 7 receptor IL7R Involved in B cell and T cell proliferation and T cell
development in thymus
205898_at Chemokine (C-X3-C motif) receptor 1 CX3CR1 Mediates adhesion and migration of leukocytes such as
monocytes, NK cells, and T lymphocytes
206978_at Chemokine (C-C motif) receptor 2 CCR2 Monocyte chemotaxis
207269_at Defensin, alpha 4, corticostatin DEFA4 Expressed in the granule of neutrophils and has
chemotactic and antimicrobial properties
217911_s_at BCL2-associated athanogene 3 BAG3 Hsp70 co-chaperone and negative regulator of apoptosis.
Also regulates development, cell motility, and autophagy
222201_s_at CASP8 associated protein 2 CASP8AP2 Regulates apoptosis and cell cycle/survival
209728_at Major histocompatibility complex,
class II, DR beta 4
HLA-DRB4 Cell surface receptor that presents exogenous peptide
antigens and is involved in T cell receptor signaling
pathway
202018_s_at Lactotransferrin /// similar to
lactotransferrin
LOC728320 /// LTF Glycoprotein that has antimicrobial and antiviral
properties
205033_s_at Defensin, alpha 1 /// defensin, alpha 3,
neutrophil-specific /// defensin alpha 1
DEFA1 /// DEFA3 ///
LOC653600 /// LOC728358
Expressed in the granule of neutrophils and has
chemotactic and antimicrobial properties
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Table A2 | Genes upregulated in HCV monoinfected subjects.
Gene ID Name Short name Function
202859_x_at Interleukin 8 IL8 Chemotactic factor that attracts neutrophils, basophils, and
T-cells and is involved in neutrophil activation
204103_at Chemokine (C-C motif) ligand 4 CCL4 Monokine involved in cellular adhesion, signaling, and
chemotaxis. Attracts NK cells and monocytes
204440_at CD83 molecule CD83 Surface marker for fully mature DC. Important for CD4(+) T
cell development in the thymus
204470_at Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating activity,
alpha)
CXCL1 Chemotactic activity for neutrophils
205067_at Interleukin 1, beta IL1B Produced by activated macrophages. Stimulates B-cell
maturation and proliferation
205114_s_at Chemokine (C-C motif) ligand 3 ///
chemokine (C-C motif) ligand 3-like 1 ///
che
CCL3 /// CCL3L1 /// CCL3L3
/// LOC728830 /// LOC730422
Monokine with inflammatory and chemokinetic properties
205207_at Interleukin 6 (interferon, beta 2) IL6 Cytokine that functions in inflammation and maturation of B
lymphocytes
205476_at Chemokine (C-C motif) ligand 20 CCL20 Chemotactic factor that attracts lymphocytes
207850_at Chemokine (C-X-C motif) ligand 3 CXCL3 Chemotactic activity for neutrophils
209774_x_at Chemokine (C-X-C motif) ligand 2 CXCL2 Chemokine produced by activated monocytes and
neutrophils and expressed at sites of inflammation
210118_s_at Interleukin 1, alpha IL1A Produced by activated macrophages and stimulates B cell
maturation and proliferation
212657_s_at Interleukin 1 receptor antagonist IL1RN Inhibits the activity of IL1
39402_at Interleukin 1, beta IL1B Produced by activated macrophages and stimulates B cell
maturation and proliferation
201925_s_at CD55 molecule, decay accelerating factor
for complement (Cromer blood group)
CD55 Integral membrane protein of erythrocytes, involved in
regulation of complement activation
202643_s_at Tumor necrosis factor, alpha-induced
protein 3
TNFAIP3 Involved in immune and inflammatory responses signaled
by cytokines through inhibition of NF-kappaB pathway
206359_at Suppressor of cytokine signaling 3 SOCS3 Negative regulator of apoptotic processes and the insulin
receptor signaling pathway
207008_at Interleukin 8 receptor, beta IL8RB Activation of neutrophils
207535_s_at Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
NFKB2 Transcription factor involved in immune and inflammatory
pathways, cellular proliferation, cellular differentiation, and
apoptosis
209795_at CD69 molecule CD69 Involved in lymphocyte proliferation
210354_at Interferon, gamma IFNG Antiviral activity and several immunoregulatory functions
214637_at Oncostatin M OSM Cytokine that regulates growth and is involved in hepatocyte
differentiation
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Table A3 | Genes up regulated in all HCV vasculitis subjects compared to others.
Gene ID Name Short name Function
201666_at TIMP metallopeptidase inhibitor 1 TIMP1 Inhibitor of metalloproteinases that degrade extracellular
matrix
205321_at Eukaryotic translation initiation factor 2,
subunit 3 gamma, 52 kDa
EIF2S3 Regulates rate of protein translation
205660_at 2′-5′-Oligoadenylate synthetase-like
protein
OASL IFN-induced cellular protein that inhibits viral replication of
HCV and EMCV
217523_at CD44 molecule (Indian blood group) CD44 Mediates cell-to-cell and cell-to-matrix interactions. Involved
in cellular migration and lymphocyte activation
223454_at Chemokine (C-X-C motif) ligand 16 CXCL16 Transmembrane chemokine that promotes cell growth and
migration, and involved in chemotaxis of T and NKT cells
224572_s_at Interferon regulatory factor 2 binding
protein 2
IRF2BP2 IRF-2 dependent transcriptional co-repressor of type I IFN
genes and many IFN-stimulated genes
1554999_at RasGEF domain family, member 1B RASGEF1B Regulation of small GTPase mediated signal transduction
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